tbuckley/cabot-search huggingface dataset:
Erratum: “Sanitary Sewer Overflows and Emergency Room Visits for Gastrointestinal Illness: Analysis of Massachusetts Data, 2006–2007”
Authors: Jyotsna S. Jagai, Stephanie DeFlorio-Barker, Cynthia J. Lin, Elizabeth D. Hilborn, Timothy J. Wade
Journal: Environmental Health Perspectives (2017)

[This corrects the article DOI: 10.1289/EHP2048.].
Surgical Nursing and the Principles of Surgery for Nurses.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply
Authors: Rachel P. Riechelmann, Monika K. Krzyzanowska
Journal: Journal of Clinical Oncology (2008)

distribution of FCOI categories among authors with positive disclosures.Research grants and employment comprised only a small proportion of the total FCOIs: 19.1% and 11.7%, and 14.3% and 2.4% for authors of clinical trials and editorials, respectively.Taken together, more than two thirds of FCOIs (69.9%) were not directly relevant to the conduct of clinical research being published.In our study, we found 34.1% of all the articles we included having one or more FCOIs with the following breakdown: clinical trials (58.3%), editorials (32.4%), other original articles (21.1%), and reviews (18.6%).When analyzed according to type of cancer, lung cancer articles had the most prevalent FCOIs (52.7%), followed by GI (40.1%), breast (35.2%), hematologic (29.6%), and genitourinary (24.1%) cancers.With regards to the monetary level of FCOI, JCO made this information available to the readers starting with the August 1, 2005, issue in a clear tabular format, but was not reported again since the November 1, 2006, issue for unknown reason.It was reassuring from the data provided by Riechelmann et al to know that the monetary values of FCOIs (employment not included) among authors of clinical trials were mostly under US$10,000 (542 of 836 or 64.8%).However, when one focuses on the FCOIs with values of Ն US$10,000, only 50.0%(147 of 294) were research grants.This suggests that clinical researchers deriving a relatively larger sum of nonresearch grantrelated money from the health industry is common.Although research evidence is lacking, it is hard not to think that not all FCOIs are the same, especially when one considers the monetary level of disclosure.In fact, the American Society of Clinical Oncology Conflict of Interest Policy arbitrarily regards de minimus payments totaling less than US$100 as exempt from disclosure requirements. 3One prominent journal uses Ն US$10,000 as a cutoff value for disclosure, 4 whereas another uses a practical alternative guideline, "Any undeclared competing financial interests that could embarrass you were they to become publicly known after your work was published." 5To our knowledge, currently none of the oncology journals (and perhaps any medical journal) disclose the monetary value of FCOIs to the readership, even though some journals routinely collect the data during manuscript submission. 6,7inally, we echo the conclusion by Riechelmann et al, that further research is necessary to understand how FCOIs affect the conduct and interpretation of research studies in oncology.To make this happen, full disclosure from authors and complete transparency from journals are necessary.
The Scientific Exhibit
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients
Authors: J. Herrstedt, J. Huober, F. Priou, H. Müller, M. Baekelandt, C. Kurzeder, J. Pfisterer, A. Stähle, I. Ray-Coquard, A. du Bois
Journal: Journal of Clinical Oncology (2009)

LBA5510 Background: One option to increase the efficacy of TC in pts with first diagnosis of ovarian cancer is to add a not cross-resistant drug. Methods: We conducted a randomized, prospective, stratified, phase III study comparing therapy with TC to TC plus gemcitabine. From 7/02 to 4/04, pts with a histological verified first diagnosis of epithelial OC, FIGO IC-IV were randomized to either TC (paclitaxel [T] 175 mg/m2 3h iv d1 + carboplatin [C] AUC 5 iv d1) or TCG (TC + gemcitabine [G] 800 mg/m2 iv d1+8) for at least 6 cycles every 21 days starting within 6 weeks post-operatively. The randomization was balanced within three strata: 1) FIGO I-IIA, 2) FIGO IIB-IIIC with residual tumor ≤ 10mm, 3) FIGO IIB-IIIC with residual tumor > 10 mm or FIGO IV. Primary endpoint is overall survival. Results: We enrolled 1,742 pts and administered 5,268 cycles TC and 5,129 cycles TCG. All baseline characteristics of the patients in both arms were well balanced. Most pts received 6+ cycles (87.2% TC, 86.2% TCG). Previous interim analyses has shown that TCG was tolerable but induced more hematological toxicity and final analysis has shown that addition of gemcitabine did not improve overall survival in patients with FIGO stage IIB-IV disease. Approximately 11% of the patients (n = 175) had FIGO stage I-IIA disease (stratum I). Most patients received 6+ cycles (93.3% TC, 86.9% TCG). With a median follow-up of 53.8 (range 0 –75) months, and using the log rank test and Cox regression analysis, no relevant differences in progression free survival (first quartile about 57 months and median ≥ 75 months in both groups, HR = 0.90 [95% CI: 0.47–1.72], p = 0.7500) and a negative trend in overall survival (first quartile ≥ 75 months in both groups, HR = 2.19 [95% CI: 0.75–6.41], p = 0.1419) were seen. Conclusions: Addition of G to TC did not improve efficacy in patients with stage I-IIA ovarian cancer. This was also the case for stratum II-III patients (previously reported). The addition of G to TC in patients with first diagnosis of ovarian cancer cannot be recommended. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly Merck
Government Services
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hematopoietic Stem Cell Gene Therapy Trial with Lentiviral Vector in X-Linked Adrenoleukodystrophy
Authors: Marina Cavazzana-Calvo, Nathalie Cartier, Salima Hacein-Bey Abina, Gabor Veres, Manfred Schmidt, Cynthia Bartholomae, Michel Vidaud, Liliane Dal-Cortivo, Laure Caccavelli, Nizar Malhaoui, Pierre Frange, Véronique Kiermer, Denice Mittelstaedt, Andrew Simmons, Céline Bellesme, François Lefrère, Chantale Lagresle, Stephane Blanche, Pierre Charneau, Muriel Audit, Bruno L’Homme, Jing Chao Zhao-Emonet, Serge Fichelson, Françoise Pflumio, Anne Dubart-Kupperschmitt, Rachel Salzman, Amber Salzman, Pierre Bougnères, Christof Von Kalle, Alain Fischer, Patrick Aubourg
Journal: Blood (2008)
Factors influencing return to work following cerebral infarction
Authors: G. Howard
Journal: JAMA (1985)

A study of 379 patients, employed before cerebral infarction and living one year afterward, was undertaken to determine what factors had influenced their returning to work. We found age, occupation, degree of disability, race, and hemisphere infarcted to be significant. Younger patients with less disability were more likely to return to work. Patients employed in professional-managerial positions were more likely to return to work than patients in blue-collar or farming positions. Although there were no racial differences following a left-hemisphere infarct, white patients were more likely to return to work following a right-hemisphere infarct. Sex, blood pressure, severity of stroke, educational level, consciousness level at admission, maximum weakness in extremities, first v repeated stroke, care by a specially trained stroke team, rehabilitation therapy, and speech did not additionally influence the probability of returning to work. (<i>JAMA</i>1985;253:226-232)
THE ETIOLOGY AND PREVENTION OF SCURVY.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic Ultrasound
Authors: M. S. Bhutani
Journal: Endoscopy (2005)

A number of interesting abstracts dealing with endoscopic ultrasound (EUS) were presented at the 2005 Digestive Disease Week (DDW) meeting in Chicago in May. Due to space limitations, all of them cannot be discussed below. I have selected some abstracts related to EUS for discussion below that were interesting, practical, or controversial. These abstracts were selected after a search in the DDW abstract CD-ROM using the key word ”EUS”. For some topics (e. g., lung cancer) I have selected abstracts on similar themes from various authors to give a view of global trends or thinking in the field. Many great ideas are sometimes independently generated at the same time by individuals with or without any connection between them.
Lungenchirurgie.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Studies in the Psychology of Sex. Erotic Symbolism, the Mechanism of Detumescence, The Psychic State in Pregnancy.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
First-Line Osimertinib Beneficial in Advanced NSCLC
Journal: Cancer Discovery (2017)

Osimertinib is more effective as first-line therapy than other EGFR inhibitors for patients with advanced EGFR-mutated non-small cell lung cancer-notably Asians, who have a higher incidence of the disease compared with Western populations. The conclusion is based on data from a subgroup analysis of the phase III FLAURA trial.
Highlights
Journal: JAMA (2015)

Eff ect of Finerenone in Patients With Diabetic Nephropathy 884In a randomized, placebo-controlled multicenter trial that enrolled 823 patients with diabetic nephropathy who were receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, Bakris and colleagues found that the addition of fi nerenone-a novel nonsteroidal mineralocorticoid receptor antagonist-improved the urinary albumin-creatinine ratio in a dose-dependent manner. Related Article 940 Molecular Diagnostic Yield in Children With ASD 895Autism spectrum disorder (ASD) represents a group of neurodevelopmental conditions that vary in clinical presentation and outcome.In a population-based sample of 258 unrelated children with ASD, Tammimies and colleagues assessed the molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing.The authors report greater diagnostic yield from genome sequencing among children with a complex or dysmorphic ASD phenotype.In an Editorial, Miles discusses genetic evaluation of children with ASD.
Stage Hypnotism
Authors: J. F. Tuthill
Journal: BMJ (1952)

<h3>Abstract</h3> <h3>Summary</h3> Ribosome profiling enables genome-wide analysis of translation with unprecedented resolution. We present <i>Ribo-seQC</i>, a versatile tool for the comprehensive analysis of Ribo-seq data, providing in-depth insights on data quality and translational profiles for cytoplasmic and organelle ribosomes. <i>Ribo-seQC</i> automatically generates platform-independent HTML reports, offering a detailed and easy-to-share basis for collaborative Ribo-seq projects. <h3>Availability</h3> Ribo-seQC is available at https://github.com/ohlerlab/RiboseQC and submitted to Bioconductor. <h3>Contact</h3> uwe.ohler@mdc-berlin.de
Regional Variations in Suicide Rates—United States, 1990-1994
Journal: JAMA (1997)

In 1994, suicides were committed by 31,142 persons in the United States (crude rate: 12.0 suicides per 100,000 population), and suicide was the ninth leading cause of death. Although rates of suicide have varied by geographic region (e.g., rates have consistently been higher in western states, reasons for these regional variations are unknown but may reflect regional differences in certain demographic variables. For example, suicide rates have been higher for males, for the elderly, and for certain racial/ethnic groups (e.g., non-Hispanic whites and American Indians/Alaskan Natives). CDC examined U.S. suicide rates from 1990 through 1994 to determine whether regional variations in suicide rates are affected by differences in age, race/Hispanic-ethnicity, and sex and to examine whether method-specific rates varied by region. This report summarizes the results of that analysis, which indicate that, despite adjustments for certain demographic variables, regional differences persist.
THE JOURNAL SPECIAL TRAIN TO DENVER.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Enterococci
Authors: CHATRCHAI WATANAKUNAKORN
Journal: Annals of Internal Medicine (1975)

Comments and Corrections1 March 1975EnterococciCHATRCHAI WATANAKUNAKORN, M.D.CHATRCHAI WATANAKUNAKORN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-82-3-425_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Hoppes and Lerner (1) in their recent article questioned the adequacy of the method used to identify enterococci in my study, because the minimum inhibitory concentration (MIC) of penicillin G for 4 of the 100 strains of enterococci that I studied was 0.1 µg/ml or less (2). They said that "if the salt tolerance test used was commercialS.[treptococcus] faecalisbroth, it would not have separatedS. bovisfrom his enterococci." However,S. faecalisbroth was not used in my study! It was stated with abundant clarity in my article that "all strains except one grew in...References1. HOPPESLERNER WP: Nonenterococcal endocarditis caused by Streptococcus bovis. Ann Intern Med 81:588-593, 1974 LinkGoogle Scholar2. WATANAKUNAKORN C: Penicillin combined with gentamicin or streptomycin: synergism against enterococci. J Infect Dis 124:581-586, 1971 CrossrefMedlineGoogle Scholar3. Difco Manual, 9th ed., Detroit, Difco Laboratories Incorporated, 1953, p. 46 Google Scholar4. FACKLAM R: Comparison of several laboratory media for presumptive identification of enterococci and group D streptococci. Appl Microbiol 26:138-145, 1973 CrossrefMedlineGoogle Scholar5. THORNSBERRYBAKERFACKLAM CCR: Antibiotic susceptibility of Streptococcus bovis and other group D Streptococci causing endocarditis. Antimicrob Agents Chemother 3:228-233, 1974 MedlineGoogle Scholar1. MOELLERINGWATSONKUNZ RBL: Endocarditis due to group D streptococci. Am J Med 57:239-250, 1974 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: CHATRCHAI WATANAKUNAKORN, M.D.Affiliations: Infectious Disease Division Department of Internal Medicine University of Cincinnati College of Medicine Cincinnati, Ohio 45267 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1975Volume 82, Issue 3Page: 425-426KeywordsMinimum inhibitory concentrationPenicillinSalts ePublished: 1 December 2008 Issue Published: 1 March 1975 PDF downloadLoading ...